Ignite Creation Date:
2024-05-06 @ 4:09 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04890366
Status:
UNKNOWN
Last Update Posted:
2022-06-06
First Post:
2021-05-11
Brief Title:
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
Sponsor:
Xuanwu Hospital Beijing
Organization:
Xuanwu Hospital Beijing
Study Overview
Official Title:
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
Status:
UNKNOWN
Status Verified Date:
2022-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate a Food and Drug Administration-approved drug for multiple sclerosis is safe and effective in combination with alteplase in patients with Acute Ischemic Stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None